跳至主要内容
临床试验/NL-OMON39240
NL-OMON39240已完成不适用

A study on the pharmacokinetics and repeatability of [18F]Fluoromethylcholine PET-CT in patients with prostate cancer - [18F]FCH pharmacokinetics and repeatability

Vrije Universiteit Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Histologically proven metastasised prostate cancer
  • 2. Written informed consent
  • 3. At least 2 tumours (metastases) per patient detected by conventional imaging (e.g., bone scan, CT or MRI of the chest, abdomen or pelvic region); conventional imaging should be recently performed (no longer than 3 months previous to the PET-CT scan)
  • 4. At least one tumour (metastasis) with a diameter equal or more than 1.5 cm (to minimize partial volume effects)
  • 5. Patients able to remain supine for 50 minutes in the PET-CT scanner
  • 1. Histologically proven metastasised prostate cancer
  • 2. Written informed consent
  • 3. At least one tumour (metastasis) with a diameter equal or more than 1.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET-CT scan)
  • 4. Patients able to remain supine for 60 minutes in the PET-CT scanner

排除标准

  • 1. Claustrophobia (part A and B);
  • 2. Multiple malignancies (part A and B);
  • 3. Anticoagulant therapy (part A).

研究者

相似试验